Top 10 Best-Selling Drugs of the 21st Century

Source: Genetic Engineering and Biotechnology News (11/6/12)

"GEN has put together a list of the top 10 best-selling drugs between 2000 and 2011. Are any of these in your medicine chest?"

It seems like you can't turn on your television or your computer nowadays without seeing another advertisement for a new prescription medicine, complete with an invitation to "ask your doctor if it's right for you!" Of these, many—some with a little help from serendipity—go on to great success. GEN has put together a list of the top 10 best-selling drugs between 2000 and 2011, based on sales figures disclosed by companies marketing the drugs in annual reports, quarterly press releases, and other publicly available materials. Are any of these in your medicine chest?

topten1 topten2 topten3 topten4

Genetic Engineering and Biotechnology News

Biotech Company Finds DNA-Targeting Drugs with AI in Canada
Source: Streetwise Reports (07/02/2025)

Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) shared AGM results and key AI-driven cancer drug milestones in Vancouver. Read why some analysts are seeing a 300% potential return

Analyst Has Confidence in Biotech's Path
Source: Dr. Joseph Pantginis (06/26/2025)

Vertex Pharmaceuticals Inc.'s (VRTX:NASDAQ) updated data is "a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D," according to an H.C. Wainwright & Co. research note.

Isotope Co. Discovers Uranium-Helium Breakthrough Potential
Source: Streetwise Reports (06/24/2025)

ASP Isotopes Inc. (ASPI:NASDAQ) is seeing at least two major transformative developments this month. Read why one analyst sees these events as positive.

Sirens of High Finance
Source: Michael Ballanger (06/23/2025)

Michael Ballanger of GGM Advisory Inc. shares his take on the current state of the market and reviews one copper stock he has been betting on for a while.

California Biotech's Trial Shows Encouraging Results
Source: Dr. Joseph Pantginis (06/20/2025)

Kura Oncology Inc.'s (KURA:NASDAQ) KOMET-007 trial results, supporting ziftomenib's benefit-risk profile for first-line acute myeloid leukemia, were encouraging, according to an H.C. Wainwright & Co. research note.